|

PD-1 Inhibitors Clinical Trials

7 actively recruiting trials

▲ +1 trial since June 2026

Also known as: Nivolumab, Pembrolizumab

Pipeline

Phase 2: 3

Top Sponsors

  • Ming-Yuan Chen2
  • Sun Yat-sen University1
  • Shandong Cancer Hospital and Institute1
  • Quanli Gao1
  • Peking University People's Hospital1

Indications

Other7 trials

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
N/A
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Phase 2
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Phase 2
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
N/A
The Immune Assessment of PD-1 Antibody Therapy in Tumor

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.